-+ 0.00%
-+ 0.00%
-+ 0.00%

Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLC

PUBT·07/21/2026 13:23:47
Listen to the news
Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLC
  • Shanghai Junshi Biosciences won Chinese regulator acceptance for a label-expansion filing for toripalimab plus platinum chemotherapy in resectable stage II-III NSCLC perioperative treatment.
  • The supplemental application seeks to broaden use from resectable stage IIIA-IIIB NSCLC to stage II-III adult patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260721-12251562), on July 21, 2026, and is solely responsible for the information contained therein.